DNABy Calypso Research6 min read

Gingko Bioworks (DNA) Q3 2025 Earnings Analysis

Genetic Missteps as DNA Dives 20.8% on Revenue Disarray

Key Takeaways

Gingko Bioworks (DNA) reported Q3 2025 earnings with revenue of $39M, representing a -56.4% year-over-year change. The stock moved -20.8% on earnings day.

The bull case: Ginkgo’s focus on productizing RAC systems and leveraging AI-driven automation positions it as a transformative force in biotechnology R&D.

The bear case: Scaling costs, slower-than-expected adoption of AI in biotech, and reliance on government partnerships pose risks to growth trajectory.

Financial Highlights

  • Revenue: $39M (-56.4% YoY)
  • Gross Profit: $26M (67.0% margin, -21.7% YoY)
  • Operating Income: $-90M (-231.8% margin, -169.8% YoY)
  • Net Income: $-81M
  • TTM Revenue: $181M

Stock Performance

  • Earnings Day Move: -20.8%
  • Year-to-Date: +1.8%
  • 1-Year Return: -15.3%
  • vs. S&P 500 (since earnings): -13.3%
  • vs. Nasdaq (since earnings): -14.5%

View live DNA data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Gingko Bioworks's Q3 2025 earnings call:

Commercial Rollout and Scaling of RAC (Reconfigurable Automation Carts) Systems

Sentiment: Positive

"Our carts are productized... we are just connecting them so that you have whatever equipment you want initially and then actually able to expand that equipment over time into bigger and bigger setups." — Jason Kelly
"I want internal milestones at Ginkgo... 50-plus scientists internally at Ginkgo ordering simultaneously from our automation system in a single day... that’s something that’s never been seen with an automated lab previously." — Jason Kelly

Long-Term Revenue Mix and Transition to Tools Business

Sentiment: Positive

"My dream by 2030 is we’re starting to put a bunch of benches to bed... 80-20 in the tools side of the house in terms of our revenue mix in 2030." — Jason Kelly
"We are largely taking over the general-purpose R&D infrastructure and being that provider of the tools into the whole industry." — Jason Kelly

AI's Role in Revolutionizing Biotechnology R&D

Sentiment: Positive

"If instead, you could basically spider these models out... running across 100 or 1,000 hypotheses in parallel as a single researcher... that is just... a fundamentally different way to pursue a goal around how does this disease work." — Jason Kelly
"The logic of the models, their ability to just do complex reasoning, is going to work... The limitation will then move to what tools can you give access to these models." — Jason Kelly

Financial Restructuring and Google Cloud Partnership Renegotiation

Sentiment: Mixed

"We were able to reduce our go-forward commitment by over $100 million and extended out the period by 2x... I think that puts us right where we want to be." — Steven Coen
"This is more a reflection of how we see the deployment of... training needs internal to Ginkgo in the future... a much smoother ramp over a longer period of time." — Jason Kelly

Government Partnerships and Biosecurity Business Growth

Sentiment: Positive

"Between our cloud security business and... the new BARDA award... we’ve been doing very well with bringing in research partnerships with the government." — Jason Kelly
"If... monitoring technology as the core pillar of biosecurity gets built worldwide... biosecurity could be 50-50 with the rest of the business." — Jason Kelly

Bull Case

Ginkgo’s focus on productizing RAC systems and leveraging AI-driven automation positions it as a transformative force in biotechnology R&D.

Bear Case

Scaling costs, slower-than-expected adoption of AI in biotech, and reliance on government partnerships pose risks to growth trajectory.

Looking Ahead

With revenue declining -56.4% year-over-year, investors will be watching for signs of a turnaround at Gingko Bioworks, particularly around commercial Rollout and Scaling of RAC (Reconfigurable Automation Carts) Systems. With operating margins at -231.8%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Gingko Bioworks's revenue in Q3 2025?

Gingko Bioworks reported Q3 2025 revenue of $39M, representing a -56.4% year-over-year change.

Did Gingko Bioworks beat earnings expectations in Q3 2025?

The stock declined -20.8% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Ginkgo’s focus on productizing RAC systems and leveraging AI-driven automation positions it as a transformative force in biotechnology R&D.

What is the bull case for DNA stock?

The bull case for DNA centers on: Ginkgo’s focus on productizing RAC systems and leveraging AI-driven automation positions it as a transformative force in biotechnology R&D.

What is the bear case for DNA stock?

The bear case for DNA centers on: Scaling costs, slower-than-expected adoption of AI in biotech, and reliance on government partnerships pose risks to growth trajectory.

How has DNA stock performed since its Q3 2025 earnings?

DNA moved -20.8% on the day of its Q3 2025 earnings report, underperforming the S&P 500 by +13.3% since earnings. Year-to-date, the stock has returned +1.8%.

Browse all 400+ earnings reports →

Learn More

Analyze DNA in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Gingko Bioworks and 400+ other stocks, explore the full platform.

Open DNA on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.